Tirzepatide does improve liver fat, but the magnitude is not comparable to what the glucagon receptor agonism in retatrutide achieves
Brazilian evidence-based guidelines for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: a joint position statement from the Brazilian Society of En-docrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of obesity and metabolic syndrome (Abeso)
[4] [5] For weight management, NICE technology appraisals (TA875 for Wegovy, TA664 for Saxenda) specify these treatments should be used within specialist weight management services (tier 3 or 4), with specific eligibility criteria, time-limited use, and defined stopping rules
I will have to consult with my doctor, but Id like to know what questions to ask
However, most effects on body weight are modest and tend to range between 2 to 4% body weight reduction (reviewed in Davidson, GLP-1R agonism in combination with the adjustable gastric band Bariatric surgery is by far the most effective therapy for weight loss reduction and improvements in glucose metabolism (Pories, 2008)